CytomX Therapeutics, Inc. (CTMX) Stock

CytomX Therapeutics, Inc. (CTMX) is a Healthcare stock trading at $3.28 (as of 2026-08-21), with a market capitalization of $714.71M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

CytomX Therapeutics, Inc. develops oncology therapeutics in the United States, including antibody-based drug candidates built on its Probody technology platform. Its pipeline includes multiple Probody therapeutics and conditionally activated antibody drug conjugates targeting cancer-associated proteins, which are being studied in clinical trials across several cancer types.

Understand CytomX Therapeutics, Inc.: how it makes money

CytomX Therapeutics develops oncology antibody therapeutics using its Probody technology platform, including antibody drug conjugates (ADCs) in Phase II trials, and it would make money if and when these candidates are approved and sold as treatments.

For CytomX, the core driver of future value is Phase II clinical outcomes for its Probody ADC candidates (for example, CX-2009 targeting CD166 and CX-2029 across multiple cancer types), where confirmed response and progression-free survival signals determine whether development can advance toward potential approval.

Business quality (Weak): The company is still in clinical development, with trial activity and efficacy, safety, and dose data as the main observable signals, but it is also running at a large operating loss in the latest quarter.

Bull case

  • Phase II clinical activity for multiple oncology programs: CX-2009 is in Phase II for breast cancer, and CX-2029 is in Phase II for several squamous and gastro-esophageal related cancers (as described in the provided company overview).
  • Efficacy signals in reported trial metrics: Reported confirmed overall response rates and progression-free survival measures include, for example, a confirmed overall response rate at 10 milligrams per kilogram of 32% and a median progression-free survival at 10 milligrams per kilogram of 7.1 (values provided).

Bear case

  • Large operating loss and no reported revenue in the latest quarter: For the quarter ended 2026-03-31, revenue is shown as 0.0B and operating margin is -191.8% (provided financial fields).
  • Safety tradeoffs reflected in adverse event metrics: Reported dose optimization safety metrics include grade 3 diarrhea rates of 10% in the first 20 optimization patients and 11% treatment discontinuations for related adverse events (values provided).
Valuation — source: SEC EDGAR (first-party)
Price$3.28
Market Cap$714.71M
Price / Book2.37
Price / Sales25.62
FCF Yield-20.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$76.20M
Net Margin-22.8%
Revenue Growth (YoY)-44.8%
FCF Growth (YoY)-12.4%
Financial Health — source: SEC EDGAR
Altman Z-Score0.58 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($150.19M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOSean A. McCarthy
Employees119
CountryUS
IPO Date2015-10-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Nuvectis Pharma, Inc. (NVCT)
  • BridgeBio Oncology Therapeutics Inc. (BBOT)
  • Monopar Therapeutics Inc. (MNPR)
  • Phathom Pharmaceuticals, Inc. (PHAT)
  • Ironwood Pharmaceuticals, Inc. (IRWD)
  • Zevra Therapeutics, Inc. (ZVRA)
  • Assembly Biosciences, Inc. (ASMB)
  • Sensei Biotherapeutics, Inc. (SNSE)
CTMX earnings history · CTMX institutional & insider holders · CTMX KPIs & operating metrics · CTMX financials · CTMX investor presentations & press releases · CTMX SEC filings · CTMX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.